← Russell 3000 cross-section

BIIB BIOGEN INC.

Trailing twelve months to 2026-03-31 · as filed 2026-04-29, not restated
Healthcare

Scale

Market cap
$32.6bn
Revenue TTM
$9.9bn
Net income TTM
$1.4bn
Free cash flow
$2.4bn
Composite score
Sector rank
#318

Valuation

P / E
23.8
EV / EBITDA
EV / sales
3.8
FCF yield
7.42%
Earnings yield vs 10-yr
-0.53pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
13.8%
EBITDA margin
ROE
7.4%
ROIC
Revenue growth
1.2%

Insider activity, last 90 days

Net open-market
$-0.24m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue compared to prior periods, and we expect that TECFIDERA revenue will continue to decline. While our portfolio is evolving, approximately three quarters of our 2025 U.S. product revenue was attributable to products that were largely manufactured in the U.S. Revenue generated from sales in Russia and Ukraine represent less than 2.0% of total revenue for the three and six months ended June 30, 2026 and 2025. …BIOGEN INC., 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →